NTLA

INTELLIA THERAPEUTICS INC

NTLA·45826J105·US·Common Stock·Healthcare - Biotechnology-13D/G

NTLA (INTELLIA THERAPEUTICS INC) is held by 155 institutional investors as of Q1 2026. Largest holders: ARK Investment Management LLC ($186M), BlackRock, Inc. ($155.8M), STATE STREET CORP ($88.7M). Net institutional sentiment: Mixed.

155
Holders
Avg rating(34 Elite)
$1.3B
Total Value
65% (171)
Fund Consensus
104 buying - 56 selling
NTLASmart Money Verdict
View all
Held by 155 funds
34 elite
Who's Trading
InsiderDPDube Michael PSell $44KJul 1, 2026
ActivistVAVanguard Capital Management5.0%Apr 30, 2026
ActivistVPVanguard Portfolio Management5.3%Apr 29, 2026
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 27, 2026
InsiderBJBASTA JAMESSell $17KMar 2, 2026
InsiderCEClark ElianaSell $8KMar 2, 2026
ActivistTHE GOLDMAN SACHS GROUP, INC.THE GOLDMAN SACHS GROUP, INC.2.7%Feb 12, 2026
ActivistCIContrarius Investment Management Ltd0.6%Feb 11, 2026
ActivistSTATE STREET CORPORATIONSTATE STREET CORPORATION5.5%Feb 9, 2026
InsiderLMLEONARD JOHN MSell $314KJan 5, 2026
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
14.5M(+2.1%)$186M1.4%-50.01%
49
Increased
12.2M(+18.3%)$155.8M0.0%+23.06%
36
Increased
6.9M(+7.8%)$88.7M0.0%-35.33%
32
New
6.2M$79.8M0.0%+4.56%
41
Increased
5.7M(+7.5%)$73.4M0.0%+24.70%
32
New
5.1M$65.2M0.0%+4.56%
41
Increased
4.7M(+74.4%)$60.3M0.0%-9.70%
44
Increased
2.9M(+5.8%)$36.6M0.0%-60.14%
31
Increased
2.7M(+212.9%)$34.5M0.0%+0.16%
47
Increased
2.3M(+20.0%)$29.7M0.0%-40.68%
34
Decreased
2.1M(-10.6%)$26.7M0.0%-19.56%
0
Increased
2.1M(+17.5%)$26.5M0.0%+17.71%
33
Decreased
2M(-10.0%)$25.3M0.0%-56.16%
0
Decreased
2M(-10.0%)$25.3M0.4%-57.23%
0
Increased
1.8M(+71.6%)$22.8M0.1%-8.46%
51
Increased
1.6M(+11.9%)$20.9M0.0%+1.67%
32
Decreased
1.6M(-7.3%)$20.7M0.1%-9.16%
0
New
1.4M$17.9M0.0%+4.56%
39
Increased
1.4M(+11.2%)$17.7M0.0%+30.27%
31
Increased
1M(+8.7%)$13M0.0%+14.14%
30

Showing 1-20 of 171

1 / 9

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used